United States Patent 7,169,401: Scope, Claims, and US Landscape for Fluorouracil in Treated Peanut-Oil Hydrating Creams
What does US 7,169,401 claim in the US market?
US 7,169,401 claims a topical, skin-hydrating medicament in a cream base where the hydrating base is refined, treated peanut oil and the active ingredient is fluorouracil (5-FU). The claim set tightly couples (1) the oil type (treated/refined/hypoallergenic), (2) oil processing method (alkali or heat treatment), and (3) in narrower dependent claims, (4) peanut-protein content expressed as <1 part per million (ppm), including specification to ara h protein.
Core claim architecture
- Independent claim (Claim 1): cream base “consisting essentially of a refined peanut oil” + active ingredient “fluorouracil.”
- Independent claim (Claim 5): cream base “consisting essentially of a hypoallergenic peanut oil” + active ingredient “fluorouracil.”
- Independent claim (Claim 10): cream base “consisting essentially of a treated peanut oil” + active ingredient “fluorouracil,” with treated peanut oil containing <1 ppm peanut protein.
Direct claim coverage in plain terms
A product can land inside the patent if it is:
- Topical (cream/medicament for skin hydration),
- Contains fluorouracil as the active, and
- Uses peanut oil that is either:
- Refined (Claim 1 family), or
- Hypoallergenic (Claim 5 family), or
- Treated to reduce peanut protein to <1 ppm (Claim 10 family),
- With optional manufacturing/process limitations:
- Oil produced by alkali treatment (Claims 3, 7, 13),
- Oil produced by heat treatment (Claims 4, 8, 14).
What is the scope of the independent claims (Claims 1, 5, 10)?
Below is claim-by-claim scope translated into decision-relevant elements.
Claim 1 (refined peanut oil cream + fluorouracil)
Claim 1 elements
- A “skin hydrating medicament” for topical use.
- A cream base that “consists essentially of” refined peanut oil.
- An active ingredient that is fluorouracil.
What “consisting essentially of” does here
- “Consisting essentially of” typically permits ingredients that do not materially affect the basic and novel characteristics (here, the basic characteristic is the refined peanut-oil cream base). That gives room for common cream excipients, but the base must still be essentially refined peanut oil and the active must be fluorouracil.
Practical breadth
- Claim 1 is broadest on processing and composition: it requires refinement but does not require a specific refinement method in the independent claim.
Claim 5 (hypoallergenic peanut oil cream + fluorouracil)
Claim 5 elements
- Topical skin hydrating cream medicament.
- Cream base “consisting essentially of” hypoallergenic peanut oil.
- Active ingredient is fluorouracil.
Practical breadth
- Similar to Claim 1, but the oil is constrained to be “hypoallergenic” rather than merely “refined.” In patent enforcement, the hypoallergenic attribute is usually supported by a protein-reduction mechanism or measurable protein threshold, even if the independent claim does not set a numeric cut-off.
Claim 10 (treated peanut oil with <1 ppm peanut protein + fluorouracil)
Claim 10 elements
- Topical skin hydrating cream medicament.
- Cream base “consisting essentially of” a treated peanut oil.
- Active ingredient is fluorouracil.
- The treated peanut oil contains less than 1 part per million peanut protein.
Practical breadth
- Claim 10 is narrower in a measurable way (protein content). It also makes the claim more defensible for enforcement and more meaningful for design-around strategies because the threshold is explicit.
How do the dependent claims narrow scope (2, 3-4, 6-9, 11-14)?
The dependent claims mainly add four categories of limitations:
- Oil concentration: 1% to 10% by weight.
- Refinement/treatment method: alkali treatment or heat treatment.
- Hypoallergenic/non-allergenic characterization (Claim 9).
- Protein specificity: ara h protein (Claim 11).
- Protein quantitative threshold: <1 ppm peanut protein already appears in Claim 10; Claim 11 narrows the identity of the protein.
Oil concentration limitation
- Claim 2 / Claim 6 / Claim 12: refined/hypoallergenic/treated peanut oil present at about 1% to about 10% by weight.
Impact
- If a formulation uses peanut oil at <1% or >10%, those dependent claims fall away. The independent claims might still be argued depending on “consisting essentially of” and whether the oil content is still consistent with “cream base consisting essentially of refined/hypoallergenic/treatment peanut oil.”
Processing method limitations
- Alkali treatment:
- Claim 3 (for refined peanut oil)
- Claim 7 (for hypoallergenic peanut oil)
- Claim 13 (for treated peanut oil)
- Heat treatment:
Impact
- These dependent claims are useful for capturing specific manufacturing routes. A competitor who uses a different processing method may avoid those particular dependent claims but can still risk infringement of Claims 1, 5, or 10 if the product composition still meets the independent limitations.
Non-allergenic statement
- Claim 9: hypoallergenic peanut oil is “non-allergenic.”
Impact
- This adds a characterization limitation. In practice, this is often treated as tied to measurable protein reduction. It can support arguments about functional equivalence and testing-backed attribute claims.
Protein identity limitation
- Claim 11: peanut protein is ara h protein.
Impact
- This limits the quantitative protein requirement to a specific peanut allergen family member. If <1 ppm is met but the remaining proteins are not ara h proteins, Claim 11 may be avoided; however, Claim 10 still requires <1 ppm total peanut protein, so the competitor still needs to control the total residual protein.
What is the effective infringement “hit zone” for competitors?
The strongest infringement risk concentrates on products that combine:
- Topical cream containing fluorouracil
- Cream base essentially peanut oil that has been refined/treatment to reduce allergenic proteins
- Potentially with 1% to 10% oil content and/or alkali/heat processing depending on how the product is made and labeled
Decision table: claim-element coverage likelihood
| Formulation design factor |
If yes |
If no |
| Active ingredient is fluorouracil |
Higher risk across all independent claims |
Low risk for the full claim set |
| Cream base is “consisting essentially of refined/hypoallergenic/treated peanut oil” |
Higher risk |
Reduced risk if base is not essentially peanut oil |
| Uses peanut oil but not refined/treatment to achieve hypoallergenic/low-protein |
Risk drops for Claims 5 and 10; Claim 1 may still be in play if “refined” is met |
Reduced |
| Residual peanut protein <1 ppm |
Moves into Claim 10 scope |
Claim 10 and dependent protein identity claim (11) likely avoidable |
| Residual peanut protein is ara h protein |
Makes Claim 11 more relevant |
Claim 11 may avoid even if Claim 10 could remain at issue |
| Peanut oil concentration 1%-10% by weight |
Adds coverage via dependent claims (2, 6, 12) |
Dependent claims avoidable, independent claims still possible depending on interpretation |
| Manufacturing route is alkali or heat |
Adds coverage via dependent claims (3-4, 7-8, 13-14) |
Those dependent claims may be avoided |
What does the patent landscape likely look like around this technology?
US 7,169,401 is positioned at the intersection of:
- Topical fluorouracil formulations (long-standing oncology/dermatology active),
- Allergenicity mitigation and protein reduction in peanut-oil processing, and
- Topical “skin hydrating” cream bases.
In a landscape sense, this creates two strong adjacent clusters:
Cluster A: Fluorouracil topical formulation patents
Typical protection in this area covers:
- Vehicle systems and emollients for topical 5-FU,
- Stabilizers, penetration enhancers, and cream rheology,
- Dosage regimens and therapeutic indications.
How 7,169,401 differentiates within Cluster A
- It does not claim “fluorouracil cream” generally. It claims fluorouracil in a cream base that is essentially treated peanut oil (refined/hypoallergenic/treated to <1 ppm peanut protein).
So, in landscape mapping, US 7,169,401 is not simply “another 5-FU cream patent.” It is an allergen-mitigated peanut-oil vehicle patent tied to fluorouracil.
Cluster B: Peanut oil allergen reduction and hypoallergenic oil processing
Typical protection in this area covers:
- Methods to refine oils,
- Residual protein reduction thresholds,
- Allergen identity and immunoreactivity management.
How 7,169,401 ties Cluster B to Cluster A
- It uses the processed peanut oil as the cream base for a fluorouracil medicament, and in Claim 10 adds a numeric residual-protein threshold.
Where this creates practical freedom-to-operate tension
- A competitor making a topical fluorouracil product with any peanut oil may face:
- claim coverage under “consisting essentially of” if the oil is the core vehicle,
- claim coverage on hypoallergenic/refined definitions,
- additional leverage if residual protein is reduced below <1 ppm.
- A competitor using fluorouracil with non-peanut hydrating oils (or peanut oil that is not refined/hypoallergenic/low-protein to the threshold) can often reduce or avoid the specific novelty of this patent.
What are likely claim-construction pressure points?
Without prosecution history, the operational pressure points are the elements that are both enforceable and design-around sensitive.
1) “Skin hydrating medicament”
Even if the product is dermatologic and has emollient function, the claim requires it is a “skin hydrating medicament” for topical use. Labeling and intended use can become evidentiary.
2) “Cream base consisting essentially of [treated peanut oil]”
This phrase makes the “base” boundary critical. If the peanut oil is only a minor additive and the cream base is dominated by other oils/surfactants/polymers, a “consisting essentially of” dispute can narrow or defeat coverage.
3) “Refined/hypoallergenic/treatment” definitions
- “Refined peanut oil” and “hypoallergenic peanut oil” depend on how the patentee supports these characteristics (often residual proteins and processing).
- “Treated peanut oil contains less than 1 ppm peanut protein” is the clearest and most measurable boundary.
4) Residual peanut protein measurement
Claim 10’s <1 ppm total peanut protein requires analytical validation. For enforcement and FTO, the test method and sampling matter, but the numerical threshold is the key commercial gate.
Design-around levers implied by the claim set
The dependent claims do not change the independent claim’s main pillars, but they define concrete levers.
Levers that most directly cut claim coverage
- Remove or replace fluorouracil (active substitution).
- Avoid peanut oil as the “consisting essentially of” base by making the base predominantly other emollients.
- If peanut-oil-based: do not meet the hypoallergenic/treatment attribute needed for Claims 5 and 10, particularly do not achieve <1 ppm peanut protein if targeting Claim 10 avoidance.
- Use alternative active ingredient with similar dermatologic effects but not fluorouracil.
Levers that mostly avoid only dependent claims
- Keep fluorouracil and treated peanut oil in place, but outside:
- 1%-10% by weight (avoids Claims 2, 6, 12),
- specific processing routes limited to alkali or heat (avoids dependent claims 3-4, 7-8, 13-14).
Commercial read: what competitors must diligence
A diligence package for potential infringers and investors should prioritize:
- Is the active fluorouracil?
- Is the vehicle essentially peanut oil? (not just an additive)
- What is the residual peanut protein level? (especially the <1 ppm question)
- What processing method is used? (alkali vs heat vs other routes)
- What allergens/proteins remain? (ara h status if Claim 11 is asserted)
Key Takeaways
- US 7,169,401 is centered on topical skin-hydrating cream formulations of fluorouracil where the cream base is essentially treated peanut oil.
- The claim set splits into three independent scopes: refined peanut oil (Claim 1), hypoallergenic peanut oil (Claim 5), and treated peanut oil with <1 ppm peanut protein (Claim 10).
- Dependent claims add enforceable narrowing via 1% to 10% oil content, alkali or heat processing, “non-allergenic” characterization, and ara h protein specificity.
- The most design-around sensitive limitation is the <1 ppm peanut protein threshold, coupled with whether peanut oil is the cream base under “consisting essentially of.”
FAQs
1) Does US 7,169,401 cover any topical fluorouracil cream?
No. It requires a cream base consisting essentially of refined/hypoallergenic/treated peanut oil plus fluorouracil.
2) Which claim is the most defensible because it has a numeric limit?
Claim 10 uses a measurable boundary: treated peanut oil contains less than 1 ppm peanut protein.
3) Can a product avoid Claims 3 and 4 by using a different processing method than alkali or heat?
It may avoid those specific dependent claims, but it can still fall within Claims 1, 5, or 10 if the product still meets their independent limitations.
4) If peanut oil is used at less than 1% by weight, is infringement still possible?
Dependent claims that require about 1% to about 10% (Claims 2, 6, 12) may be avoidable, but independent claims can still be implicated if the cream base is still essentially refined/hypoallergenic/treated peanut oil.
5) What is the design-around most directly tied to allergen control?
Avoid meeting the residual peanut protein requirement for Claim 10, especially staying above the <1 ppm threshold, or avoiding an essentially peanut-oil-based cream base.
References
[1] US Patent 7,169,401.
